While many investors are familiar with examples of smaller biotech firms delivering jaw-dropping intraday gains on the back of positive clinical trial news or FDA approvals, stock picking to that effect is exceptionally difficult,” acknowledges the author of today’s article. One solution to this is the ETF he highlights that focuses on smaller biotech stocks, many of which “are in a sweet spot for takeover activity” as big pharma companies flush with cash go shopping for acquisition targets. For more on this biotech ETF and its many benefits, CLICK HERE.
This Biotech ETF’s Holdings “Are In A Sweet Spot For Takeover Activity”
- by RobH
